The downgrade from Outperform to Sector Perform by a major analyst firm, along with a drastic reduction in the price target, is likely to negatively impact investor sentiment and the stock price of Spruce Biosciences in the short term. Such a significant adjustment suggests a reassessment of the company's future growth prospects or operational performance, which can lead to decreased investor confidence and selling pressure.